Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882627 | 0.87 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL6884988 | 0.87 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6882528 | 0.86 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL7676441 | 0.86 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6874478 | 0.86 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6879154 | 0.85 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6881702 | 0.84 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL6874486 | 0.84 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6872565 | 0.83 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL6881335 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-04 | — | — | US | claimed |
| US-6486172-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF BENZAMIDE OR BENZOCARBONYLSULFIDE SUBSTITUTED 1-AZABICYCLO(2,2,2)OCT-3-YL COMPOUNDS TO TREAT THE CONDITIONS ASSOCIATED WITH DEFECTS OF NICOTINIC SUBTYPES BRAIN RECEPTORS | PHARMACIA & UPJOHN COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | UGT1A1, NAT1, SLC10A1 | CHRNB2 595/4885CHRNA4 594/4885CHRNA7 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.